Citius Pharmaceuticals is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 22 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.93 |
|---|---|
| 52-week range | $0.48 - $1.19 |
| 50-day moving average | $0.66 |
| 200-day moving average | $0.73 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.23 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9309 from 2024-07-25
| 1 week (2024-07-19) | 17.57% |
|---|---|
| 1 month (2024-06-27) | 45.86% |
| 3 months (2024-04-26) | 40.03% |
| 6 months (2024-01-26) | 36.86% |
| 1 year (2023-07-27) | -14.60% |
|---|---|
| 2 years (2022-07-27) | 3.90% |
| 3 years (2021-07-27) | 1.89 |
| 5 years (2019-07-26) | 1.18 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -25.08% |
| Return on equity TTM | -42.15% |
| Profit margin | 0% |
| Book value | $0.50 |
| Market Capitalization | $143.1 million |
TTM: trailing 12 months
We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.
Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.
Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.48 up to $1.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.682. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Its biologics license application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma is under review by the FDA. Its LYMPHIR also received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, the company is developing CITI-002 (Halo-Lido), which is in Phase 2b trial for the relief of hemorrhoids.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.